Home / Stocks / Beta Drugs Limited
BETA

Beta Drugs Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,764.2

Change

-38.1 (-2.11%)

Open

₹1,790.4

Prev. Close

₹1,802.3

Day High

₹1,808.6

Day Low

₹1,732.2

Volume Analysis

Traded

45,866

Delivered

19,032

Delivery %

41.49%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (21.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year revenue growth (19.2%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,880.86 ₹1,844.73 ₹1,804.46 ₹1,768.33 ₹1,728.06 ₹1,691.93 ₹1,651.66
Fibonacci ₹1,844.73 ₹1,815.55 ₹1,797.51 ₹1,768.33 ₹1,739.15 ₹1,721.11 ₹1,691.93
Camarilla ₹1,785.21 ₹1,778.21 ₹1,771.2 ₹1,768.33 ₹1,757.2 ₹1,750.19 ₹1,743.19

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+14.16%

1 Week

-4.04%

1 Month

+5.98%

3 Months

-24.21%

6 Months

+28.15%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹602.29

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

10.57%

Net margin 11.94% × asset turnover 0.59x × equity multiplier 1.5x

Company Overview

Sector

Healthcare

Market Cap

₹1,990 Cr

P/E (TTM)

38.3

ROE

18.8%

Book Value

₹394.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Beta Drugs Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Financial Strength (100/100), while Cash Flow (21/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%); promoter holding is falling. Strong 3-year revenue growth (19.2%).

TopFund Score — Fundamentals Quality

60/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

87

Valuation

30

Cash Flow

21

Corporate Governance

43

Momentum

44

Institutional Ownership

55

Business Quality

79

Risk & Volatility

41

Liquidity

41

From Screener.in

  • +Company has reduced debt.
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Promoter holding has decreased over last 3 years: -7.82%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Trading window closed from 16 Nov 2026 to 21 Nov 2026 ahead of board meeting.

Brickwork report for quarter ended September 30, 2026 shows no deviation in Rs 117.01 crore preferential issue proceeds.

Updates 02 Nov

Board approved Q2/H1 FY27 results on 22 Oct 2026; H1 consolidated revenue rose 29.2% to Rs 263.04 Cr.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 88 94 100 103 87 94 126 137
Expenses + 70 76 81 82 70 76 98 107
Operating Profit 18 17 20 21 17 18 27 30
OPM % 21.0% 18.0% 20.0% 21.0% 19.0% 19.0% 22.0% 22.0%
Other Income + -1 2 3 3 2 3 2 2
Interest 2 3 3 4 4 4 3 2
Depreciation 3 4 4 4 4 5 4 5
Profit before tax 12 12 16 16 10 12 22 26
Tax % 25.0% 26.0% 25.0% 26.0% 19.0% 24.0% 25.0% 25.0%
Net Profit + 9 9 12 12 9 9 16 19
EPS in Rs 9 9 12 12 8 9 14 17
Raw PDF — — — — — — — —
YoY Sales growth — — — — -1 0 25 33

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 51 66 91 116 184 227 296 362 384 444
Expenses + 41 54 73 91 141 174 236 287 309 352
Operating Profit 9 12 18 25 43 53 60 75 76 92
OPM % 19.0% 18.0% 20.0% 21.0% 23.0% 23.0% 20.0% 21.0% 20.0% 21.0%
Other Income + 0 0 0 0 1 1 1 2 11 9
Interest 1 1 3 2 2 2 3 7 15 13
Depreciation 2 3 4 7 7 10 10 13 17 18
Profit before tax 7 8 12 16 34 41 49 57 54 70
Tax % 1.0% -2.0% 21.0% 27.0% 28.0% 25.0% 25.0% 26.0% 24.0% —
Net Profit + 7 8 9 12 25 31 36 42 41 53
EPS in Rs 7 9 9 12 25 30 36 42 41 48
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 30 38 28 58 24 30 22 6 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 24 32 48 59 83 113 148 187 235 427
Borrowings + 8 20 23 17 21 20 15 138 148 49
Other Liabilities + 9 22 28 31 45 55 82 101 103 170
Total Liabilities 50 83 107 118 158 198 254 436 496 656
Fixed Assets + 13 18 44 40 55 63 65 89 125 220
CWIP 1 15 0 3 0 0 0 0 0 9
Investments 0 0 0 1 1 1 0 0 0 0
Other Assets + 35 50 63 74 102 135 190 347 371 427
Total Assets 50 83 107 118 158 198 254 436 496 656
Equity Capital 9 9 10 10 10 10 10 10 10 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 17 0 8 19 30 23 31 36 37
Cash from Investing Activity + -11 -21 -15 -6 -22 -19 -14 -36 -51
Cash from Financing Activity + 5 12 9 -8 -1 -2 -7 118 -8
Net Cash Flow 12 -9 2 5 7 2 9 118 -22
Free Cash Flow 9 -21 -7 13 10 5 19 -1 -16
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 181 1 47 75 69 44 52 48 49

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 66.73% → 58.91%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 32.92% 32.87% 32.25% 31.95% 31.95% 32.2% 32.11% 32.07% 32.07% 32.06% 33.65% 33.27%
Promoters 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 64.9% 64.63% 59.1% 58.91%
FII 0.32% 0.32% 0.9% 1.16% 1.15% 0.9% 0.9% 0.9% 1.14% 1.16% 1.02% 1.37%
DII 0.02% 0.06% 0.12% 0.16% 0.17% 0.17% 0.26% 0.29% 1.9% 2.15% 6.23% 6.45%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Beta Drugs Limited (this stock) 1,990 38.3 4.54 18.8%
Hester Biosciences Ltd 1,992 33.9 4.26 15.9%
Venus Remedies Limited 2,002 16.4 2.84 15.6%
Windlas Biotech Limited 2,067 31.1 3.64 12.2%
Syncom Formu (i) Ltd 1,907 20.0 4.06 17.6%
Indoco Remedies Ltd. 2,079 — 2.03 -9.36%
Panacea Biotec Ltd 2,171 — 2.6 -2.42%

Which Mutual Funds Hold Beta Drugs Limited?

Frequently Asked Questions about Beta Drugs Limited

Community Sentiment

What are other investors saying about Beta Drugs Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.